Femasys Obtains FDA Approval for Advanced FemVue Diagnostic Device
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Yahoo Finance
FDA Clearance Announcement: Femasys Inc. has received FDA 510(k) clearance for its FemVue Controlled device, which integrates FemVue and FemChec technologies to enhance fallopian tube evaluation and improve clinical workflows.
Device Functionality: The FemVue Controlled device is designed for controlled delivery of saline and air as contrast media during ultrasound imaging, allowing for multiple clinical applications, including confirming tubal patency.
Company's Commitment: CEO Kathy Lee-Sepsick emphasized that this clearance marks a significant milestone in Femasys' mission to provide practical, clinician-focused innovations that simplify care delivery and enhance product efficiency.
Broader Product Portfolio: Femasys is focused on making fertility and non-surgical permanent birth control more accessible, with products like FemaSeed for infertility treatment and FemBloc for non-surgical sterilization, both demonstrating high effectiveness and patient satisfaction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FEMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FEMY
Wall Street analysts forecast FEMY stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.870
Low
3.00
Averages
4.75
High
6.50
Current: 3.870
Low
3.00
Averages
4.75
High
6.50
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Femasys Regains Compliance with Nasdaq Listing Requirements
- Compliance Milestone: Femasys Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, successfully resolving regulatory issues and securing continued listing status, which enhances investor confidence.
- Strategic Focus: CEO Kathy Lee-Sepsick emphasized that this development is an important milestone for the company and its shareholders, indicating a continued focus on advancing strategic priorities in reproductive health solutions and building long-term value.
- Innovative Product Portfolio: Femasys is commercializing a portfolio of fertility and permanent birth control innovations, including FemaSeed Intratubal Insemination, which has shown more than double the pregnancy rate of traditional intrauterine insemination in clinical data, highlighting significant market potential.
- Clinical Trial Progress: FemBloc, the first non-surgical, in-office permanent birth control alternative, is currently undergoing the pivotal FINALE trial aimed at securing U.S. FDA approval, further solidifying the company's market position in reproductive health.
See More
Femasys Regains Nasdaq Compliance, Focuses on Strategic Growth
- Compliance Regained: Femasys announced it has regained compliance with Nasdaq's minimum bid price requirement, removing a significant overhang on the stock, which is expected to boost investor confidence and stabilize share prices.
- Strategic Focus: CEO Kathy Lee-Sepsick stated that the company will now concentrate on advancing its strategic priorities, particularly expanding access to its reproductive health products, thereby enhancing its competitive position in the market.
- Market Performance: Despite regaining compliance, Femasys shares are trading approximately 1.28% lower at around $3.96, indicating a cautious market sentiment regarding the company's future performance.
- Long-term Value Creation: The company is committed to creating long-term shareholder value, with expectations to enhance overall performance and market share through strategic investments and product expansion.
See More
Femasys Regains Nasdaq Compliance Status
- Compliance Regained: Femasys Inc. announced it has received formal notice from Nasdaq confirming compliance with the minimum bid price requirement, marking a significant development for the company and boosting shareholder confidence.
- Strategic Focus: CEO Kathy Lee-Sepsick stated that with compliance restored, the company will continue to focus on advancing its strategic priorities and expanding access to innovative reproductive health solutions, thereby enhancing long-term value.
- Product Innovation: Femasys's FemaSeed® product demonstrated more than double the pregnancy rate of traditional IUI in clinical trials, with a comparable safety profile, indicating its competitive edge and market potential in fertility treatments.
- Global Market Expansion: FemBloc®, the first non-surgical permanent contraception option, has received full regulatory approval in Europe, the UK, and New Zealand, with commercialization expected through strategic partnerships in select markets, furthering the company's global footprint in reproductive health.
See More
Femasys Appoints New COO John Canning to Drive Operations
- Executive Appointment: Femasys announced the appointment of John Canning as COO, who brings over 25 years of medical device experience, having previously served as COO and CTO at Terumo Aortic, emphasizing the company's commitment to enhancing operational efficiency.
- Strategic Acquisition Expertise: Canning played a key role in the acquisition of Bolton Medical during his tenure at Terumo Aortic, and this experience is expected to bolster Femasys's competitiveness in future M&A activities, driving business expansion.
- Stock Option Incentive: The company granted Canning an option to purchase 150,000 shares at an exercise price equal to the closing price on the grant date, aiming to attract and retain executive talent while enhancing commitment to the company's long-term growth.
- Stock Price Reaction: Femasys's shares rose by 5.93%, reflecting a positive market response to the new COO appointment, indicating increased investor confidence in the company's future operations and strategic direction.
See More
Femasys Reports FY Loss with Revenue of $2.29M
- Earnings Loss: Femasys reported a FY GAAP EPS of -$0.47, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Revenue Performance: The company generated revenue of $2.29 million, which, while a positive inflow, still falls short of covering operational costs, highlighting the need for improvements in its business model sustainability.
- Cash Position: As of December 31, 2025, Femasys had approximately $9.3 million in cash and cash equivalents, but with an accumulated deficit of about $145.8 million, the company faces significant financial pressure.
- Operational Outlook: The company expects its current cash reserves to fund operations into the third quarter of 2026; however, ongoing losses and high accumulated deficits may limit future growth potential.
See More
Femasys Grants Stock Options to New Employees
- Stock Option Grant: Femasys granted 185,000 stock options to two new employees in February 2026, with exercise prices set at $0.50 and $0.57, reflecting the company's commitment to incentivizing new talent.
- Vesting Schedule: The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting at 25% each year over the next three years, ensuring long-term employee retention and contribution.
- Market Positioning and Innovation: Femasys focuses on developing fertility and non-surgical permanent birth control products, with its FemaSeed and FemBloc offerings providing a unique competitive edge, particularly in European and international markets.
- Clinical Trials and Regulatory Progress: Femasys's FemBloc product received regulatory approvals in Europe, the UK, and New Zealand in 2025, and is currently undergoing the FINALE pivotal trial for FDA approval, indicating strong growth potential in the reproductive health sector.
See More
Femasys Regains Compliance with Nasdaq Listing Requirements
- Compliance Milestone: Femasys Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, successfully resolving regulatory issues and securing continued listing status, which enhances investor confidence.
- Strategic Focus: CEO Kathy Lee-Sepsick emphasized that this development is an important milestone for the company and its shareholders, indicating a continued focus on advancing strategic priorities in reproductive health solutions and building long-term value.
- Innovative Product Portfolio: Femasys is commercializing a portfolio of fertility and permanent birth control innovations, including FemaSeed Intratubal Insemination, which has shown more than double the pregnancy rate of traditional intrauterine insemination in clinical data, highlighting significant market potential.
- Clinical Trial Progress: FemBloc, the first non-surgical, in-office permanent birth control alternative, is currently undergoing the pivotal FINALE trial aimed at securing U.S. FDA approval, further solidifying the company's market position in reproductive health.
See More
Femasys Regains Nasdaq Compliance, Focuses on Strategic Growth
- Compliance Regained: Femasys announced it has regained compliance with Nasdaq's minimum bid price requirement, removing a significant overhang on the stock, which is expected to boost investor confidence and stabilize share prices.
- Strategic Focus: CEO Kathy Lee-Sepsick stated that the company will now concentrate on advancing its strategic priorities, particularly expanding access to its reproductive health products, thereby enhancing its competitive position in the market.
- Market Performance: Despite regaining compliance, Femasys shares are trading approximately 1.28% lower at around $3.96, indicating a cautious market sentiment regarding the company's future performance.
- Long-term Value Creation: The company is committed to creating long-term shareholder value, with expectations to enhance overall performance and market share through strategic investments and product expansion.
See More
Femasys Regains Nasdaq Compliance Status
- Compliance Regained: Femasys Inc. announced it has received formal notice from Nasdaq confirming compliance with the minimum bid price requirement, marking a significant development for the company and boosting shareholder confidence.
- Strategic Focus: CEO Kathy Lee-Sepsick stated that with compliance restored, the company will continue to focus on advancing its strategic priorities and expanding access to innovative reproductive health solutions, thereby enhancing long-term value.
- Product Innovation: Femasys's FemaSeed® product demonstrated more than double the pregnancy rate of traditional IUI in clinical trials, with a comparable safety profile, indicating its competitive edge and market potential in fertility treatments.
- Global Market Expansion: FemBloc®, the first non-surgical permanent contraception option, has received full regulatory approval in Europe, the UK, and New Zealand, with commercialization expected through strategic partnerships in select markets, furthering the company's global footprint in reproductive health.
See More
Femasys Appoints New COO John Canning to Drive Operations
- Executive Appointment: Femasys announced the appointment of John Canning as COO, who brings over 25 years of medical device experience, having previously served as COO and CTO at Terumo Aortic, emphasizing the company's commitment to enhancing operational efficiency.
- Strategic Acquisition Expertise: Canning played a key role in the acquisition of Bolton Medical during his tenure at Terumo Aortic, and this experience is expected to bolster Femasys's competitiveness in future M&A activities, driving business expansion.
- Stock Option Incentive: The company granted Canning an option to purchase 150,000 shares at an exercise price equal to the closing price on the grant date, aiming to attract and retain executive talent while enhancing commitment to the company's long-term growth.
- Stock Price Reaction: Femasys's shares rose by 5.93%, reflecting a positive market response to the new COO appointment, indicating increased investor confidence in the company's future operations and strategic direction.
See More
Femasys Reports FY Loss with Revenue of $2.29M
- Earnings Loss: Femasys reported a FY GAAP EPS of -$0.47, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Revenue Performance: The company generated revenue of $2.29 million, which, while a positive inflow, still falls short of covering operational costs, highlighting the need for improvements in its business model sustainability.
- Cash Position: As of December 31, 2025, Femasys had approximately $9.3 million in cash and cash equivalents, but with an accumulated deficit of about $145.8 million, the company faces significant financial pressure.
- Operational Outlook: The company expects its current cash reserves to fund operations into the third quarter of 2026; however, ongoing losses and high accumulated deficits may limit future growth potential.
See More
Femasys Grants Stock Options to New Employees
- Stock Option Grant: Femasys granted 185,000 stock options to two new employees in February 2026, with exercise prices set at $0.50 and $0.57, reflecting the company's commitment to incentivizing new talent.
- Vesting Schedule: The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting at 25% each year over the next three years, ensuring long-term employee retention and contribution.
- Market Positioning and Innovation: Femasys focuses on developing fertility and non-surgical permanent birth control products, with its FemaSeed and FemBloc offerings providing a unique competitive edge, particularly in European and international markets.
- Clinical Trials and Regulatory Progress: Femasys's FemBloc product received regulatory approvals in Europe, the UK, and New Zealand in 2025, and is currently undergoing the FINALE pivotal trial for FDA approval, indicating strong growth potential in the reproductive health sector.
See More
